

Nebraska Medicaid DUR Board Meeting
Tuesday September 9th, 2025

DUR Board Members in attendance: Marin Broucek, M.D., Matt Titchener R.P., Charlie Moore, R.P., Jaci Timmons, M.D., David Randolph, R.P.

Nebraska Medicaid and LTC attendees in attendance: Lee Stutzman, R.P., Pharmacy Director, Leah Spencer, R.N. Program Specialist, Dianne Garside, R.P., Spencer Moore, R.P.

Contracted attendees: Jamie Benson, R.P., Nebraska Total Care; Kimberly Broyles-kpogli, R.P., Molina Healthcare, Shaleigh Hammons, Account Executive, Prime Therapeutics, Sandy Pranger, R.P., Sr. Director Clinical Account Services Prime Therapeutics

Public Attendees in attendance: Amy Hornig, Abbvie; Suzanne Hansen, Gilead; Jodi Fuehrer, Renewal Health Outreach; Jon Freeland, Novo Nordisk; Randy Roth, Merck

I. Opening and Introductions

Lee Stutzman called the meeting to order at 6:30pm. The meeting was held at the Best Western Plus Lincoln Inn & Suites in Lincoln, NE. A copy of the open meetings act was available.

II. Declaration of any Conflict of Interest or changes

No conflicts or changes were stated.

III. Agenda approval

Motion was brought to approve the agenda by Broucek with a second by Titchener. The vote was as follows: Broucek-yes, Moore-yes, Randolph-absent, Timmons-absent, Titchener-yes

IV. Review and Approval of Minutes from previous Board meeting May 13th, 2025

Motion was brought to approve the agenda by Titchener with a second by Broucek. The vote was as follows: Broucek-yes, Moore-yes, Randolph-absent, Timmons-absent, Titchener-yes

V. Update on Recommendations from Previous Meeting

Stutzman announced the state will plan to review annual Support Act Data, do PA form reviews on opioid dependence treatments (buprenorphine/naloxone and buprenorphine) and insulin like growth factor, and bring information about Hepatitis C Preferred Drug List compliance at the next meeting on Oct 28th.

VI. Retrospective DUR

Old Business – None

New Business

Spencer Moore presented data on concomitant use of GLP-1s and DPP4s. Low rates of concomitant use were noted. Titchener motioned to notify prescribers via a letter that concomitant use of GLP1s and DPP4 medications is not recommended. The vote was as follows: Broucek-yes, Moore-yes, Randolph-absent, Timmons-yes, Titchener-yes

Stutzman presented data on high-cost drugs. After Board discussion no further action was taken.

VII. Prospective DUR

Old Business

Garside presented the PA form and criteria for Growth Hormone for its annual review. A motion was brought to approve the PA form and criteria by Broucek. The vote was as follows: Broucek-yes, Moore-yes, Randolph-yes, Timmons-yes, Titchener-yes

New Business

Sandy Pranger (Prime Therapeutics) presented State draft criteria form on new drug review, Journavx. After Board discussion, Titchener motioned to approve amended drafted criteria. The vote was as follows: Broucek-yes, Moore-yes, Randolph-yes, Timmons-yes, Titchener-yes

The Board discussed the proposal to lower the age limit of Naltrexone. Titchener motioned to approve lowering the age of approved use from 18 down to 12 years. The vote was as follows: Broucek-yes, Moore-yes, Randolph-yes, Timmons-yes, Titchener-yes

VIII. Special Requests from the Department – None

IX. Future Meeting Dates

October 28th, 2025

X. Concerns and Comments from the DUR Board

Board members raised a concern about patients getting started on newly FDA-approved medications and the cost issues associated with newer drugs compared to using lower cost, traditional drugs.

XI. Concerns and Comments from the DUR Director - None

XII. Concerns and Comments from the State DHHS Representatives - None

XIII. Concerns and Comments from the MCO Representatives - None

XIV. Concerns and Comments from the Public Attendees - None

XV. Adjournment

The motion was brought by Titchener and seconded by Broucek to adjourn the meeting. The motion was unanimously approved. Meeting adjourned at 7:36pm.